Phaseline

Companies › Kriya Therapeutics

Kriya Therapeutics: clinical trials, targets and expected readouts

6 active drug programs in 7 registered trials: 7 Phase 1; Metabolic and endocrine, Ophthalmology, Neurology; next expected readout Dec 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
VV-14295 (KRIYA-825)
Adeno-associated virus (AAV) vector delivering a soluble fms-like tyrosine kinase-1 (sFlt-
CFBPhase 1Geographic Atrophy Secondary to Age-related Macular DegenerationDec 2027
VV-14303
Gene therapy vector
–Phase 1Metabolic Dysfunction-associated Steatohepatitis (MASH)Jul 2028
VV-14305 (KRIYA-586)
Gene therapy for thyroid eye disease
–Phase 1Thyroid Eye Disease (TED)Aug 2028
VV-14300
Gene therapy designed to help remove excess sugar from blood
–Phase 1Type 1 Diabetes MellitusNov 2028
RP-008 (KRIYA-748)
Gene therapy
–Phase 1Trigeminal NeuralgiaFeb 2029
VV-14299
Gene therapy designed to work with VV-14300 to help remove excess sugar from blood
–Phase 1Type 1 Diabetes MellitusJul 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06765980VV-14295 (KRIYA-825)Phase 1Geographic Atrophy Secondary to Age-related Macular DegenerationOphthalmologyDec 2027
NCT07732400VV-14303Phase 1Metabolic Dysfunction-associated Steatohepatitis (MASH)Metabolic and endocrineJul 2028
NCT07404111VV-14305 (KRIYA-586)Phase 1Thyroid Eye Disease (TED)OphthalmologyAug 2028
NCT07831798VV-14300Phase 1Type 1 Diabetes MellitusMetabolic and endocrineNov 2028
NCT07596485RP-008 (KRIYA-748)Phase 1Trigeminal NeuralgiaNeurologyFeb 2029
NCT07829302VV-14300Phase 1Type 1 Diabetes MellitusMetabolic and endocrineJul 2029
NCT07829302VV-14299Phase 1Type 1 Diabetes MellitusMetabolic and endocrineJul 2029

From the company's SEC filings

Private offerings reported to the SEC (Form D)

Targets

CFB (1)

Companies with the same targets

Regeneron Pharmaceuticals Novartis Suzhou Sanegene Bio Nanjing Chia-tai Tianqing Pharmaceutical

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.